Severity
Critical
FDA Drug recall · Reported January 29, 2025
Marketed without an Approved NDA/ANDA; FDA laboratory analysis confirmed product tainted with undeclared metformin and glyburide
Shoppers- Plaza recalled FOUZEE SugarLin HERBAL FORMULA capsules, 180 capsules per bottle, Sold and Distributed by… - a critical-severity action.
FOUZEE SugarLin HERBAL FORMULA capsules, 180 capsules per bottle, Sold and Distributed by… was recalled by Shoppers- Plaza in January 29, 2025. Reason: Marketed without an Approved NDA/ANDA; FDA laboratory analysis confirmed product tainted with undeclared metf…. Check the official notice for the remedy. Verify recall #D-0207-2025 with the FDA Drug before acting.
The recall
Shoppers- Plaza issued this critical-severity FDA Drug recall-Marketed without an Approved NDA/ANDA; FDA laboratory analysis confirmed product tainted with undeclared metf….
Sourced from official FDA Drug enforcement records. Verify recall #D-0207-2025 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0207-2025) was formally reported on January 29, 2025, with the manufacturer initiating the action on December 16, 2024. It is classified under Critical severity (Class I), with a current status of Ongoing. Shoppers- Plaza is listed as the recalling firm, operating out of Hawthorne, CA. Federal records list the affected scope as 172 180-count bottles.
The documented reason for this recall is: Marketed without an Approved NDA/ANDA; FDA laboratory analysis confirmed product tainted with undeclared metformin and glyburide Distribution data in the federal record shows the product reached: Nationwide via internet sales. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 3,731 children & baby products recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
172 180-count bottles
Related Recalls
6
0 from same agency
FOUZEE SugarLin HERBAL FORMULA capsules, 180 capsules per bottle, Sold and Distributed by Shoppers-Plaza, Hawthorne, CA 90250. Product of India. UPC 8 26656 69047 7
Marketed without an Approved NDA/ANDA; FDA laboratory analysis confirmed product tainted with undeclared metformin and glyburide
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Ongoing |
| Recall number | D-0207-2025 |
| Date reported | January 29, 2025 |
| Date initiated | December 16, 2024 |
| Recalling firm | Shoppers- Plaza |
| Firm location | Hawthorne, CA |
| Affected scope | 172 180-count bottles |
| Distribution | Nationwide via internet sales |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Xishentang Dongguan Trading Co, Ltd., dba Pretty-Life, of China · 2026-07-02
Diamond Wipes International, Inc. of Chino, California · 2026-07-02
· 2026-07-02
· 2026-07-02
Sanven Technology Ltd., dba Vevor, of Rancho Cucamonga, California · 2026-07-02
Compare this recall with AMASKY Nursing Pillows Recalled Due to Risk of Serious Inju… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported January 29, 2025. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.